About AVT
Browse Articles
Authors
Customer Services

Original article

Recent trends in early stage response to combination antiretroviral therapy in Australia

Hamish McManus, Jennifer F Hoy, Ian Woolley, Mark A Boyd, Mark D Kelly, Brian Mulhall, Norman J Roth, Kathy Petoumenos, Matthew G Law, the Australian HIV Observational Database

Corresponding author name: Hamish McManus
Corresponding author e-mail: hmcmanus@kirby.unsw.edu.au

Citation: Antiviral Therapy 2015; 20:131-139
doi: 10.3851/IMP2774

Date accepted: 16 March 2014
Date published online: 04 April 2014

Abstract

Background: There have been improvements in combination antiretroviral therapy (cART) over the past 15 years. The aim of this analysis was to assess whether improvements in ART have resulted in improvements in surrogates of HIV outcome.

Methods: Patients in the Australian HIV Observational Database who initiated treatment using mono/duo therapy prior to 1996, or using cART from 1996 onwards, were included in the analysis. Patients were stratified by era of ART initiation. Median changes in CD4+ T-cell count and the proportion of patients with detectable HIV viral load (>400 copies/ml) were calculated over the first 4 years of treatment. Probabilities of treatment switch were estimated using the Kaplan–Meier method.

Results: A total of 2,753 patients were included in the analysis: 28% initiated treatment <1996 using mono/duo therapy and 72% initiated treatment ≥1996 using cART (30% 1996–1999, 12% 2000–2003, 11% 2004–2007 and 19% ≥2008). Overall CD4+ T-cell count response improved by later era of initiation (P<0.001), although 2000–2003 CD4+ T-cell count response was less than that for 1996–1999 (P=0.007). The average proportion with detectable viral load from 2 to 4 years post-treatment commencement by era was: <1996 mono/duo 0.69 (0.67–0.71), 1996–1999 cART 0.29 (0.28–0.30), 2000–2003 cART 0.22 (0.20–0.24), 2004–2007 cART 0.09 (0.07–0.10) and ≥2008 cART 0.04 (0.03–0.05). Probability of treatment switch at 4 years after initiation decreased from 53% in 1996–1999 to 29% after 2008 (P<0.001).

Conclusions: Across the five time-periods examined, there have been incremental improvements for patients initiated on cART, as measured by overall response (viral load and CD4+ T-cell count) and also increased durability of first-line ART regimens.

<< BACK

Copyright © Nucleus Global 2017. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.